| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-43312-0.5mg | |||
| BSA Free | NBP1-43312-0.05mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB110-55376SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-117SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-725SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-65543SS | |||
| Azide and BSA Free | NBP2-80661 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-78039SS | |||
| Azide and BSA Free | NBP2-80921 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-64895SS | |||
| Azide and BSA Free | NBP2-80651 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56581SS | |||
![Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Analysis using the PE conjugate of NBP1-43312. Analysis of mouse splenocyte suspensions using MHC Class II PE and can be used at less than or equal to 0.125 ug per test. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.](http://images.novusbio.com/fullsize/MHC-Class-II-Antibody-M5-114-15-2-Flow-Cytometry-NBP1-43312-img0009.jpg "Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Analysis using the PE conjugate of NBP1-43312. Analysis of mouse splenocyte suspensions using MHC Class II PE and can be used at less than or equal to 0.125 ug per test. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test.")
![Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Staining of C57BL/6 splenocytes with 0.06 ug of Rat IgG2b K Isotype Control Purified (cat. NBP1-43323) (open histogram) or 0.06 ug of Anti-Mouse MHC Class II (I-A/I-E) Purified (filled histogram) followed by Anti-Rat IgG FITC (cat. NBP1-69751). Total viable cells were used for analysis.](http://images.novusbio.com/fullsize/MHC-Class-II-Antibody-M5-114-15-2-Flow-Cytometry-NBP1-43312-img0001.jpg)
![Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Analysis using the Allophycocyanin conjugate of NBP1-43312. Staining of C57BL/6 splenocytes with Anti-Mouse CD3e FITC and 0.015 micrograms of Rat IgG2b ? Isotype Control APC (left) or 0.015 micrograms of Anti-Mouse MHC Class II (I-A/I-E) APC (right).](http://images.novusbio.com/fullsize/MHC-Class-II-Antibody-M5-114-15-2-Flow-Cytometry-NBP1-43312-img0006.jpg)
![Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Analysis using the Biotin conjugate of NBP1-43312. Staining of C57BL/6 splenocytes with 0.015 ug of Rat IgG2b K Isotype Control Biotin (open histogram) or 0.015 ug of Anti-Mouse MHC Class II (I-A/I-E) Biotin followed by Streptavidin PE (filled histogram).](http://images.novusbio.com/fullsize/MHC-Class-II-Antibody-M5-114-15-2-Flow-Cytometry-NBP1-43312-img0007.jpg)
![Flow Cytometry: MHC Class II Antibody (M5/114.15.2) [NBP1-43312] - Analysis using the FITC conjugate of NBP1-43312. Staining of C57BL/6 splenocytes with Anti-Mouse CD3e and 0.06 micrograms of Rat IgG2b k Isotype Control FITC (left) or 0.06 micrograms of Anti-Mouse MHC Class II (I-A/I-E) FITC (right). Cells in the lymphocyte gate were used for analysis.](http://images.novusbio.com/fullsize/MHC-Class-II-Antibody-M5-114-15-2-Flow-Cytometry-NBP1-43312-img0008.jpg)
![TGF-beta signaling inhibits immunological characteristics of myofibers through activating the IRE1 alpha pathway. Western blot analyses of the expression changes of Smad pathway proteins, IRE1 alpha and PERK pathway proteins, and immunological molecules in MPC-myotubes isolated from SM TGF-beta r2−/− mice, with or without 48 h stimulation of IFN-gamma /LPS and/or SRI (A); 24 or 48 h stimulation of IFN-gamma /LPS, SRI, 4-PBA, 4μ8C (IRE1 alpha pathway inhibitor) or GSK (PERK pathway inhibitor) (B, D). The relative protein expression values are expressed as a ratio [protein of interest/GAPDH or phosphorylated (P) protein/total (T) protein]. C mRNA levels of IL-1 beta , IL-6, and MCP-1 in MPC-myotubes isolated from SM TGF-beta r2−/− mice, with or without 48 h stimulation of IFN-gamma /LPS, SRI and/or 4-PBA,analyzed by qPCR. All data are presented as means +/- SD (n = 3). A one-way ANOVA was used for multiple comparisons (*P < 0.05; **P < 0.01) Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/36849929), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-43312_rat-monoclonal-mhc-class-ii-i-a-i-e-antibody-m5-114-15-2-western-blot-13220261457494.jpg)
![Intrinsic TGF-beta signaling affects muscle cell immune behaviors by prompting UPR activity under pro-inflammatory conditions. The protein levels of IRE1 alpha and eIF2 alpha (A), H-2Kb, H2-E alpha , and TLR3 (B) in control or SM TGF-beta r2−/− mice-derived MPC-myotubes, with or without stimulation of IFN-gamma /LPS, Tg, or TM, were analyzed by Western blot. The relative protein expression values are expressed as a ratio [protein of interest/GAPDH or phosphorylated (P) protein/total (T) protein]. C mRNA levels of IL-1 beta , IL-6, and MCP-1 in MPC-myotubes with or without 48 h stimulation of IFN-gamma /LPS, Tg, or TM, analyzed by qPCR. All data are presented as means +/- SD (n = 3). A one-way ANOVA was used for multiple comparisons (*P < 0.05; **P < 0.01) Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/36849929), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-43312_rat-monoclonal-mhc-class-ii-i-a-i-e-antibody-m5-114-15-2-western-blot-13220261534476.jpg)
![TGF-beta signaling inhibits immunological characteristics of myofibers through activating the IRE1 alpha pathway. Western blot analyses of the expression changes of Smad pathway proteins, IRE1 alpha and PERK pathway proteins, and immunological molecules in MPC-myotubes isolated from SM TGF-beta r2−/− mice, with or without 48 h stimulation of IFN-gamma /LPS and/or SRI (A); 24 or 48 h stimulation of IFN-gamma /LPS, SRI, 4-PBA, 4μ8C (IRE1 alpha pathway inhibitor) or GSK (PERK pathway inhibitor) (B, D). The relative protein expression values are expressed as a ratio [protein of interest/GAPDH or phosphorylated (P) protein/total (T) protein]. C mRNA levels of IL-1 beta , IL-6, and MCP-1 in MPC-myotubes isolated from SM TGF-beta r2−/− mice, with or without 48 h stimulation of IFN-gamma /LPS, SRI and/or 4-PBA,analyzed by qPCR. All data are presented as means +/- SD (n = 3). A one-way ANOVA was used for multiple comparisons (*P < 0.05; **P < 0.01) Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/36849929), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-43312_rat-monoclonal-mhc-class-ii-i-a-i-e-antibody-m5-114-15-2-western-blot-132202615335818.jpg)
![TGF-beta signaling inhibits immunological characteristics of myofibers through activating the IRE1 alpha pathway. Western blot analyses of the expression changes of Smad pathway proteins, IRE1 alpha and PERK pathway proteins, and immunological molecules in MPC-myotubes isolated from SM TGF-beta r2−/− mice, with or without 48 h stimulation of IFN-gamma /LPS and/or SRI (A); 24 or 48 h stimulation of IFN-gamma /LPS, SRI, 4-PBA, 4μ8C (IRE1 alpha pathway inhibitor) or GSK (PERK pathway inhibitor) (B, D). The relative protein expression values are expressed as a ratio [protein of interest/GAPDH or phosphorylated (P) protein/total (T) protein]. C mRNA levels of IL-1 beta , IL-6, and MCP-1 in MPC-myotubes isolated from SM TGF-beta r2−/− mice, with or without 48 h stimulation of IFN-gamma /LPS, SRI and/or 4-PBA,analyzed by qPCR. All data are presented as means +/- SD (n = 3). A one-way ANOVA was used for multiple comparisons (*P < 0.05; **P < 0.01) Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/36849929), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-43312_rat-monoclonal-mhc-class-ii-i-a-i-e-antibody-m5-114-15-2-western-blot-1322026159715.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Total protein from HeLa, MCF7 and mouse brain was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TARDBP in 1% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0012.jpg "Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Total protein from HeLa, MCF7 and mouse brain was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-TARDBP in 1% block buffer and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - HeLa cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with TDP-43/TARDBP Antibody conjugated to Alexa Fluor 488 (NB110-55376AF488) at 10 ug/ml for 1 hour at room temperature. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - HeLa cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-TARDBP at 2 ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0011.jpg)
![Immunohistochemistry-Paraffin: TDP-43/TARDBP Antibody [NB110-55376] - Analysis of FFPE human placenta using TDP-43 antibody at 1:250 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Nuclear staining was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunohistochemistry-Paraffin-NB110-55376-img0010.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - TARDBP antibody was tested in HeLa WCE.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0004.jpg)
![Western Blot: TDP-43/TARDBP Antibody [NB110-55376] - Cells were transfected with the pCMV6-ENTRY control or pCMV6-ENTRY TARDBP cDNA for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-TARDBP.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Western-Blot-NB110-55376-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - TARDBP antibody was tested in MCF-7 cells with DyLight 488 (Green). Nuclei and alpha-tubulin were counterstained with DAPI (Blue) and DyLight 550 (Red).](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - Analysis using the DyLight 550 conjugate of NB110-55376. Staining of Human iPS derived neurons, fixed in 4% formaldehyde solution. NB110-55376R was diluted 1:200. All antibodies were diluted in PBS/BSA 3% (w/v) ) Triton X-100 0,3 % (v/v). Images taken by an Arrayscan (Cellomics). Blue dots in TDP staining is Hoechst.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: TDP-43/TARDBP Antibody [NB110-55376] - Subcellular distribution of TDP-43 and CWC22 in control DRG sensory neurons. TDP-43 was stained diffusely in the nucleus, excluding SMN foci in sensory neurons. Scale bar: 10 um. Image collected and cropped by CiteAb from the following publication (//dmm.biologists.org/lookup/doi/10.1242/dmm.028225) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TDP-43-TARDBP-Antibody-Immunocytochemistry-Immunofluorescence-NB110-55376-img0013.jpg)
![Immunohistochemistry-Paraffin: beta-Defensin 3 Antibody [NB200-117] - Distribution of hBD-2 and hBD-3 in normal oral epithelium. Formalin fixed and parafilm embedded normal human oral tissue was labeled with an anti-hBD-2 specific primary antibody, and detected with an AF488 conjugated secondary antibody. hBD-3 was labeled with a rabbit anti-hBD-3 (Novus Biologicals Inc., Littleton, CO, USA), specific primary antibody and detected using an AF594 (purple) conjugated donkey anti-rabbit (Invitrogen). Note green fluorescence detection of hBD-2 localized to the stratum spinosum and stratum granulosum, while pink/red fluorescence detects hBD-3 exclusively to the stratum basale. hBD-1, not shown, is localized to the same regions as hBD-2. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fimmu.2012.00294/abstract) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/beta-Defensin-3-Antibody-Immunohistochemistry-Paraffin-NB200-117-img0002.jpg "Immunohistochemistry-Paraffin: beta-Defensin 3 Antibody [NB200-117] - Distribution of hBD-2 and hBD-3 in normal oral epithelium. Formalin fixed and parafilm embedded normal human oral tissue was labeled with an anti-hBD-2 specific primary antibody, and detected with an AF488 conjugated secondary antibody. hBD-3 was labeled with a rabbit anti-hBD-3 (Novus Biologicals Inc., Littleton, CO, USA), specific primary antibody and detected using an AF594 (purple) conjugated donkey anti-rabbit (Invitrogen). Note green fluorescence detection of hBD-2 localized to the stratum spinosum and stratum granulosum, while pink/red fluorescence detects hBD-3 exclusively to the stratum basale. hBD-1, not shown, is localized to the same regions as hBD-2. Image collected and cropped by CiteAb from the following publication (//journal.frontiersin.org/article/10.3389/fimmu.2012.00294/abstract) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: beta-Defensin 3 Antibody [NB200-117] - Analysis of beta-Defensin 3 in human skin.](http://images.novusbio.com/fullsize/Defensin-beta-3-Antibody-Immunohistochemistry-Paraffin-NB200-117-img0001.jpg)
![Immunohistochemistry: beta-Defensin 3 Antibody - BSA Free [NB200-117] - Topical application of PALA enhances AMP production in human skin explants. (a) HBD2 protein levels are increased in tissue homogenates of infected human skin explants by PALA or Neosporin treatment. Human skin biopsies were infected with MRSA for 1 h & then treated with the indicated ointments for 24 hours in triplicate. HBD2 levels were measured in tissue homogenates by ELISA (n = 3–4 donors). Mean ± SD; significance determined by 1-way ANOVA & Bonferroni multiple comparison test; *p  0.05. (d) Immunohistochemistry staining of HBD3 in MRSA infected human skin explants described in (a). Representative image of 4 donors. (e) LL-37 protein levels are increased in tissue homogenates of infected human skin explants by PALA treatment. LL-37 levels were measured in tissue homogenates described in (a) by ELISA (n = 4–5 donors). Mean ± SD; significance determined by 1-way ANOVA & Bonferroni multiple comparison test; *p < 0.05. (f) Immunohistochemistry staining of LL-37 in MRSA infected human skin explants described in (a). Representative image of 6 donors. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29880914), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-117_rabbit-polyclonal-beta-defensin-3-antibody-310202416212331.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b in HeLa Cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:20 overnight at 4C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody. LAMP2 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0012.jpg "Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b in HeLa Cells. Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:20 overnight at 4C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody. LAMP2 staining (green), F-Actin staining with Phalloidin (red) and nuclei with DAPI (blue) is shown. Images were taken at 60X magnification.")
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Normal deparaffinized Human placenta tissue tissues stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0015.jpg)
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Both normal and cancer biopsies of deparaffinized Human prostate carcinoma tissues stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0016.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Analysis of 25ug of NRK cell lysates using anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0017.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Validation of subcellular fractionation and immunocytochemistry. RLC proteins are present at ER microsomes. Lysates from 7 DIV cortical neurons were subjected to differential centrifugation to isolate nuclear pellet (P1), postnuclear supernatant (PNS), mitochondrial pellet (P2), and ER microsomal pellet (P3), as depicted in the graphic on the right. Image collected and cropped by CiteAb from the following publication (www.onlinelibrary.wiley.com/doi/10.15252/embr.201744853) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0020.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Cells were grown on chamber slides and fixed with formaldehyde prior to staining. Cells were probed without (control) or with a LAMP-2/CD107b polyclonal antibody at a dilution of 1:100 overnight at 4 C, washed with PBS and incubated with a DyLight-488 conjugated secondary antibody and nuclei with DAPI (blue) is shown.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0019.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Analysis of 10 ug of HeLa (left panel), NIH/3T3 (middle panel) and NRK (right panel) whole cell lysates using anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Western-Blot-NB300-591-img0018.jpg)
![Immunocytochemistry/Immunofluorescence: LAMP-2/CD107b Antibody [NB300-591] - Analysis of LAMP-2/CD107b (green) in NIH/3T3 cells.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunocytochemistry-Immunofluorescence-NB300-591-img0013.jpg)
![Immunohistochemistry-Paraffin: LAMP-2/CD107b Antibody [NB300-591] - Both normal and cancer biopsies of deparaffinized Human tonsils were stained with anti-LAMP-2/CD107b.](http://images.novusbio.com/fullsize/LAMP-2-CD107b-Antibody-Immunohistochemistry-Paraffin-NB300-591-img0014.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - Exposure of rat primary microglial cells (rPMs) to combined antiretroviral therapy (cART) cocktail resulted in impaired lysosomal function. rPMs were seeded into six-well plates & treated with cART (5 µM each of tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), & dolutegravir (DTG)) for the indicated time periods. (A,B) Exposure of microglia to cART resulted in a significant decrease in expression of lysosomal-associated membrane protein 2 (LAMP2) at 6 to 24 h post-treatment. (C) Representative bar graph showing cART-mediated significantly increased lysosomal membrane permeabilization (LMP) (24 h). (D,E) Microglia exposed to cART demonstrated a significant decrease in levels of mature cathepsin D (mCTSD) at 24 h post-treatment. (F) Representative bar graph showing exposure of cART significantly reduced the CTSD activity in rPMs (24 h). (G) Representative bar graph showing cART-mediated increased lysosomal pH in rPMs. (H,I) Acridine orange staining showing increased green color & reduced red color in cART-treated rPMs. H2O2 was used as a positive control for lysosome damage. Data is from three independent experiments. Actin beta (ACTB) served as a protein loading control for western blots. Data are expressed as means ± SEM & were analyzed using student t-test or one-way ANOVA. *, p < 0.05 vs. control; N.S., non-significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31569373), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-591_rabbit-polyclonal-lamp-2-cd107b-antibody-310202416175213.jpg)
![Western Blot: LAMP-2/CD107b Antibody [NB300-591] - HSPA overexpression abrogated cART-mediated impairment of lysosomal function. Control rPMs & heat shock protein family A (HSPA) overexpressing rPMs were seeded into six-well plates subjected to various treatments for 24 h. Protein homogenates were prepared for the detection of the indicated molecules. (A,B) Representative western blots showing overexpressing HSPA in rPMs reversed cART-mediated downregulation of LAMP2 & mCTSD expression levels. (C) Representative bar graph showing overexpression of HSPA in rPMs protected lysosomal pH. (D,E) Representative bar graphs showing HSPA protected LMP (D), & CTSD activity (E) in cART-treated rPMs. For all western blots, ACTB served as a protein loading control. Data is from three independent experiments & is expressed as means ± SEM & were analyzed using student t-test or one-way ANOVA. *, p < 0.05 vs. control; #, p < 0.05 vs. cART. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31569373), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-591_rabbit-polyclonal-lamp-2-cd107b-antibody-31020241618933.jpg)
![Western Blot: LYVE-1 Antibody [NB100-725] - Western Blot: [NB100-725] - Total protein from human stomach, lymph node and placenta was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-LYVE1 in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Western-Blot-NB100-725-img0027.jpg "Western Blot: LYVE-1 Antibody [NB100-725] - Western Blot: [NB100-725] - Total protein from human stomach, lymph node and placenta was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-LYVE1 in 1% milk, and detected with an anti-rabbit HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry-Paraffin: LYVE-1 Antibody [NB100-725] - Analysis using the DyLight 488 conjugate of NB100-725. Staining of LYVE1 in paraffin embedded MDA-MB-231 breast cancer orthotopic transplantation tissue. Image courtesy of product review submitted by Luana Schito.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-Paraffin-NB100-725-img0028.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human lung blood vessels using NB100-725. Note presence of RBCs within vessel lumen.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0011.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - Analysis using the DyLight 488 conjugate of NB100-725. Unlabeled control with labeled samples of cells dissociated mechanically and enzymatically from human skin. Image provided via product review by Patricia Redondo.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0024.jpg)
![Western Blot: LYVE-1 Antibody [NB100-725] - Analysis of extracts from A549 cells using LYVE1 antibody (NB100-725, 1:100). Image from verified customer review.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Western-Blot-NB100-725-img0018.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - LYVE1 antibody was tested at 1:400 in A549 cells using an Alexa Fluor 488 secondary (shown in green) alongside unstained cells (shown in red).](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0016.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on A549 cells with LYVE-1 Antibody NB100-725 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Rabbit IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 550 (SA5-10033, Thermo Fisher).](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0031.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human bladder vasculature using NB100-725.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0012.jpg)
![Immunohistochemistry: LYVE-1 Antibody [NB100-725] - Detection of LYVE1 in endothelial cells of human lung blood vessels using NB100-725.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Immunohistochemistry-NB100-725-img0013.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - Analysis using the Alexa Fluor (R) 488 conjugate of NB100-725. Staining of LYVE1 in human dissociated skin lyve1+ using AF488 conjugated anti-LYVE1 antibody. Image from verified customer review.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0023.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on A549 cells with LYVE-1 Antibody NB100-725G (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 10 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Dylight 488.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0029.jpg)
![Flow Cytometry: LYVE-1 Antibody [NB100-725] - An intracellular stain was performed on K562 cells with LYVE-1 Antibody NB100-725C (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 650.](http://images.novusbio.com/fullsize/LYVE-1-Antibody-Flow-Cytometry-NB100-725-img0030.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0006.jpg "Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus.")
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus with MOUSE ANTI RAT CD90 (THY 1.1).](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0001.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymocytes.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0002.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymocytes.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0003.jpg)
![Flow Cytometry: CD90/Thy1 Antibody (OX-7) [NB100-65543] - Staining of rat thymus cell.](http://images.novusbio.com/fullsize/CD90-Thy1-Antibody-OX-7-Flow-Cytometry-NB100-65543-img0004.jpg)
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0008.jpg "Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - Effect of various p65-inhibitor peptides on binding of purified recombinant p65 protein to the DNA in vitro. Recombinant p65 protein (100 ng/sample) was incubated for 30 minutes with 50uM of various peptides in 0.025 ml and then assayed for DNA binding activity by EMSA (Please refer to Takada et al, 2004 for further details).")
![Blocking/Neutralizing: RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - PTD-p65-P1 peptide inhibits TNF-induced NF-kB activation: KBM-5 cells were incubated with various concentrations of peptides for 1 hr and treated with 0.1nM TNF for 30 min. Nuclear extracts were prepared and NF-kB activation was analyzed by EMSA (Please refer to Takada et al, 2004 for further details).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-[p-Ser276]-Inhibitor-Peptide-Set-Blocking-Neutralizing-NBP2-26505-img0009.jpg)
![Functional (Inhibition): RelA/NFkB p65 [p Ser276] Inhibitor Peptide Set [NBP2-26505] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-26505) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/RelA-NFkB-p65-p-Ser276-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-26505-img0010.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Lane 1: Rabbit IgG whole molecule. Lane 2: Rabbit IgG F(ab) Fragment. Lane 3: Rabbit IgG F(c) Fragment. Lane 4: Rabbit IgM Whole Molecule. Lane 5: Normal Rabbit Serum. All samples were reduced. Load: 50 ng per lane. Block: incubated with blocking buffer for 30 min at RT. Primary Antibody: Anti-Rabbit IgG (H&L) (GOAT) Antibody 1:1,000 for 60 min at RT. Secondary antibody: Anti-Goat IgG (DONKEY) Peroxidase Conjugated Antibody 1:40,000 in incubated with blocking buffer for 30 min at RT. Predicted/Observed Size: 25 and 50 kDa for Rabbit IgG and Serum, 25 kDa for F(c) and F(ab), 70 and 23 kDa for IgM. Rabbit F(c) migrates slightly higher. Image from the Alkaline Phosphatase version of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Western-Blot-NBP1-72732-img0021.jpg "Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Lane 1: Rabbit IgG whole molecule. Lane 2: Rabbit IgG F(ab) Fragment. Lane 3: Rabbit IgG F(c) Fragment. Lane 4: Rabbit IgM Whole Molecule. Lane 5: Normal Rabbit Serum. All samples were reduced. Load: 50 ng per lane. Block: incubated with blocking buffer for 30 min at RT. Primary Antibody: Anti-Rabbit IgG (H&L) (GOAT) Antibody 1:1,000 for 60 min at RT. Secondary antibody: Anti-Goat IgG (DONKEY) Peroxidase Conjugated Antibody 1:40,000 in incubated with blocking buffer for 30 min at RT. Predicted/Observed Size: 25 and 50 kDa for Rabbit IgG and Serum, 25 kDa for F(c) and F(ab), 70 and 23 kDa for IgM. Rabbit F(c) migrates slightly higher. Image from the Alkaline Phosphatase version of this antibody.")
![Immunocytochemistry/Immunofluorescence: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - DyLight 488 conjugated anti-Rabbit IgG was used to demonstrate 2 color STED immunofluorescence microscopy. Methanol fixed A431 cells were blocked with normal goat serum. The cells were then probed with 0.4 ug/mL final concentration of anti-HDAC and detected with 0.2 ug/mL DyLight488 conjugated Anti-RABBIT IgG [GOAT] secondary antibody (colored GREEN). Also shown in this 2-color STED image is a-tubulin monoclonal antibody [MOUSE] detected with ATTO 425 conjugated anti-MOUSE IgG [GOAT] secondary antibody (colored RED). Image from the DyLight 488 version of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Immunocytochemistry-Immunofluorescence-NBP1-72732-img0019.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Lane 1: Rabbit IgG. Load: 100 ng per lane. Primary antibody: RABBIT IgG (H&L) Antibody Pre-adsorbed at 1:1,000 for overnight at 4C. Secondary antibody: DyLight 800 goat secondary antibody 1:20,000 for 30 min at RT. Block: incubated with blocking buffer for 30 min at RT. Predicted/Observed size: 55 and 28 kDa for Rabbit IgG.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Western-Blot-NBP1-72732-img0007.jpg)
![Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Western Blot: Goat anti-Rabbit IgG (H+L) Secondary Antibody [Rhodamine] [NB7575] - Lane 1: Rabbit IgG. Load: 50 ng per lane. Primary antibody: None. Secondary antibody: Rhodamine goat secondary antibody at 1:1,000 for 60 min at RT. Block: incubated with blocking buffer for 30 min at RT. Predicted/Observed size: 25 & 55 kDa for Rabbit IgG.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Western-Blot-NBP1-72732-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Image from the DyLight 488 version of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Immunocytochemistry-Immunofluorescence-NBP1-72732-img0018.jpg)
![Fluorophore-linked immunosorbent assay: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - Using the DyLight 405 format of this antibody.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-Fluorophore-linked-immunosorbent-assay-NBP1-72732-img0026.jpg)
![SDS-Page: Goat anti-Rabbit IgG (H+L) Secondary Antibody (Pre-adsorbed) [NBP1-72732] - SDS-Page of Goat anti-Rabbit IgG (H+L) Secondary Antibody [Unconjugated] (Pre-adsorbed).Lane 1: Goat anti-Rabbit IgG - Non-Reduced.Lane 2: Goat anti-Rabbit IgG - Reduced.Load: 1.0 ug per lane.Predicted/Observed size: 25 & 55 kDa - Reduced, 160 kDa - Non-Reduced for Goat IgG.Other Band(s): None.](http://images.novusbio.com/fullsize/Goat-anti-Rabbit-IgG-H+L-Secondary-Antibody-Pre-adsorbed-SDS-Page-NBP1-72732-img0025.jpg)
![Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Western-Blot-NB100-78039-img0006.jpg "Western Blot: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Analysis of human tonsil (1), human spleen (2), and human lymph node (3) tissue using CD162 antibody at a concentration of 2 ug/ml.")
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Human tonsil tissue stained with PSGL-1/CD162 Antibody (HECA-452) at 5ug/mL, and Leica Refine DAB kit. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/PSGL-1-CD162-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0014.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD3+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody [F0101B, R&D Systems]. A co-stain was performed using CD3 antibody NBP2-25186APC.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0008.jpg)
![Immunohistochemistry-Paraffin: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - IHC analysis of formalin-fixed paraffin-embedded tissue section of human breast adenocarcinoma using CLA antibody (clone HECA-452) at 5 ug/ml concentration. The antibody generated a membrane-cytoplasmic staining in the cancerous cells of breast adenocarcinoma. Note:- Besides lymphocytes, CLA has been shown to be present on cells of normal endometrium as well as breast cancer tissues (PMID 19625313 and 22970241).](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Immunohistochemistry-Paraffin-NB100-78039-img0004.jpg)
![Flow Cytometry: PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - Human peripheral blood lymphocytes stained with purified HECA-452, followed by anti-mouse IgG FITC](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cytometry-NB100-78039-img0005.jpg)
![Flow (Cell Surface): PSGL-1/CD162 Antibody (HECA-452) [NB100-78039] - Cutaneous Lymphocyte Antigen (CLA) Antibody (HECA-452) [NB100-78039] - A cell surface stain was performed on CD14+ hPBMCs with Cutaneous Lymphocyte Antigen (CLA) antibody (HECA-452) NB100-78039 and a matched isotype control NBP2-31379. Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature, followed by rat-Dylight 488 conjugated secondary antibody. A co-stain was performed using CD14 antibody NB100-77758AF488.](http://images.novusbio.com/fullsize/Cutaneous-Lymphocyte-Antigen-CLA-Antibody-HECA-452-Flow-Cell-Surface-NB100-78039-img0007.jpg)
![In vivo assay: IKK gamma Inhibitor Peptide Set [NBP2-26504] - NBD peptide blocks constitutive NF-kB as shown by EMSA. U266 cells were treated with 100 uM of control or NBD peptide for different time periods. Nuclear extracts were isolated and checked for NF-kB-DNA binding activity.](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-In-vivo-assay-NBP2-26504-img0010.jpg "In vivo assay: IKK gamma Inhibitor Peptide Set [NBP2-26504] - NBD peptide blocks constitutive NF-kB as shown by EMSA. U266 cells were treated with 100 uM of control or NBD peptide for different time periods. Nuclear extracts were isolated and checked for NF-kB-DNA binding activity.")
![In vivo assay: IKK gamma Inhibitor Peptide Set [NBP2-26504] - NBD peptide blocks constitutive NF-kB activation in human multiple myeloma cells. U266 cells were treated with 100 uM of control (A & B) or NBD peptide (C & D) for 12 hr, cytospun, plated on glass slides, air dried for 1 hr at room temperature and fixed with cold acetone. Slides were blocked with 5% normal goat serum for 1 hr and then incubated with rabbit polyclonal anti-human p65 antibody (A & C) followed by Ig-Alexa 594 second step. In control peptide treated cells, p65 translocates to nucleus (A), whereas NBD peptide prevents translocation of p65 into the nucleus (C). B & D: Nuclear staining with DNA binding dye.](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-In-vivo-assay-NBP2-26504-img0012.jpg)
![IKK gamma Inhibitor Peptide Set [NBP2-26504] - The IKK complex consists of IKKalpha + IKKbeta+ NEMO. NEMO (IKKgamma/NF-kB Essential MOdulator) is a scaffold protein required for the kinase activity of IKKalpha + IKKbeta. NBD (NEMO Binding Domain) inhibits formation of the IKK complex (IKKalpha + IKKbeta+ NEMO) by binding to NEMO and blocking IKK complex formation. In this regard, NBD is considered to be an 'IKKalpha and IKKBeta decoy' Blocking IKK complex formation suppresses downstream events in the NF-kB signaling pathway that rely on the IKK complex including phosphorylation of IkBalpha, and subsequence IkBalpha ubiquination, degradation and release of NF-kB. Hence, NF-kB is retained in the cytoplasm in its inactive state.](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-NBP2-26504-img0014.jpg)
![Functional (Inhibition): IKK gamma Inhibitor Peptide Set [NBP2-26504] - TLR5/NF-kB/SEAPorter HEK 293 (NBP2-26277) cells were plated in 96-well plates at 5 x 10^4 cells/well for 16 h. Cells were preincubated with different concentrations (0, 1, 5, 10, 25 and 50 uM) of Inhibitory Peptide (NBP2-26504) and Control Peptide (NBP2-29334) for 1 h. Cells were then stimulated with 1 ng/ml Flagellin (NBP2-25289) for 24 h. Secreted alkaline phosphatase (SEAP) was analyzed using SEAPorter Assay Kit (NBP2-25285). *p < 0.05 versus control peptide at the corresponding concentrations (Mann-Whitney U test).](http://images.novusbio.com/fullsize/IKK-gamma-Inhibitor-Peptide-Set-Functional-Inhibition-NBP2-26504-img0016.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0005.jpg "Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using Alexa Fluor (R) 488 conjugate of CD45 antibody (OX-1). Rat Splenocytes were stained with CD45 antibody (OX-1) [NB100-64895] (blue) and a matched isotype control [NBP2-27287] (orange). Cells were incubated in an antibody dilution of 1 ug/mL for 20 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 488.")
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Analysis using the FITC conjugate of CD45 antibody (OX-1). Staining of rat spleen cells.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0004.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) - BSA Free [NB100-64895] - Representative sequential gating during flow cytometry analysis of rat non-parenchymal liver cells (n = 4). Cells were labeled with antibodies to SE-1 (NB110-68095AF488), CD31, and CD45 (NB100-64895PE). LSECs were then identified as SE-1-Alexa488+ cells (e), and the biexponential CD45-PE/CD31-APC of events (f) were used to display and select the CD45+ CD31+ subsets of LSECs. FMOs (used for gating), and single antibody staining controls are shown in Additional file. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/33246411/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-BSA-Free-Flow-Cytometry-NB100-64895-img0006.jpg)
![Flow Cytometry: CD45 Antibody (OX-1) [NB100-64895] - Staining of rat peripheral blood lymphocytes with mouse anti-rat CD45 antibody (OX-1) [NB100-64895].](http://images.novusbio.com/fullsize/CD45-Antibody-OX-1-Flow-Cytometry-NB100-64895-img0001.jpg)
![Western Blot: TLR4 Antibody [NB100-56581] - Analysis of TLR4 using NB100-56581 at 2 ug/mL on partial recombinant mouse TLR4 protein.](http://images.novusbio.com/fullsize/TLR4-Antibody-Western-Blot-NB100-56581-img0008.jpg "Western Blot: TLR4 Antibody [NB100-56581] - Analysis of TLR4 using NB100-56581 at 2 ug/mL on partial recombinant mouse TLR4 protein.")
![Immunocytochemistry/Immunofluorescence: TLR4 Antibody [NB100-56581] - TLR4 antibody was tested in PC-12 cells with FITC (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/TLR4-Antibody-Immunocytochemistry-Immunofluorescence-NB100-56581-img0007.jpg)
![Immunohistochemistry-Paraffin: TLR4 Antibody [NB100-56581] - Analysis of TLR4 in FFPE mouse spleen tissue using NB100-56581 (A) and mouse isotype control (B) at 5 mg/mL.](http://images.novusbio.com/fullsize/TLR4-Antibody-Immunohistochemistry-Paraffin-NB100-56581-img0009.jpg)